Trial · NCT00752986

ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial

NCT00752986, Phase 2, Terminated, Genzyme, a Sanofi Company; results first posted 2014-10-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial. Trials, record NCT00752986. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00752986

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial
NCT number: NCT00752986
Status: Terminated
Phases: Phase 2
Enrollment: 39 participants, actual
Lead sponsor: Genzyme, a Sanofi Company
Conditions: Breast Cancer
Interventions: ZD6474 (Vandetanib at the dose of 100 mg), Placebo to match ZD6474 (Vandetanib at the dose of 100 mg), Fulvestrant, ZD6474 (Vandetanib at the dose of 300 mg), Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)
First posted: 2008-09-16
Last updated: 2016-12-05
Other registries' IDs: eudract:2008-000579-12
Results first posted: 2014-10-06

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Event Free Survival	Restaging (RECIST) is carried out at screening and every 3 months during the study until 1 year and than every 6 months until objective disease progression.	Success rate (patients without progression and still on treatment at 24 weeks
Secondary	Time-To-Progression, Progression-Free Survival, Objective Tumor Response Rate (CR+PR), Disease Control Rate (CR+PR+SD) and Duration of Response (DOR)	Restaging (RECIST) is carried out at screening and every 3 months during the study until 1 year and than every 6 months until objective disease progression.
Secondary	Overall Survival	Assessments for survival must be made at the 60 day follow-up visit and then every 3 months, unless the patient withdraws consent.
Secondary	Incidence and Type of Adverse Events (AEs), Clinically Significant Laboratory or Vital Sign Abnormalities and Electrocardiographic (ECG) Changes	Continuous assessment of safety.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame
PRIMARY	Event Free Survival	Restaging (RECIST) is carried out at screening and every 3 months during the study until 1 year and than every 6 months until objective disease progression.
SECONDARY	Time-To-Progression, Progression-Free Survival, Objective Tumor Response Rate (CR+PR), Disease Control Rate (CR+PR+SD) and Duration of Response (DOR)	Restaging (RECIST) is carried out at screening and every 3 months during the study until 1 year and than every 6 months until objective disease progression.
SECONDARY	Overall Survival	Assessments for survival must be made at the 60 day follow-up visit and then every 3 months, unless the patient withdraws consent.
SECONDARY	Incidence and Type of Adverse Events (AEs), Clinically Significant Laboratory or Vital Sign Abnormalities and Electrocardiographic (ECG) Changes	Continuous assessment of safety.

Source ClinicalTrials.gov

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Vandetanib at the Dose of 100 mg	16
Overall Study	STARTED	Vandetanib at the Dose of 300 mg	12
Overall Study	STARTED	Placebo to Match Vandetanib 100 mg and 300 mg	11
Overall Study	COMPLETED	Vandetanib at the Dose of 100 mg	11
Overall Study	COMPLETED	Vandetanib at the Dose of 300 mg	11
Overall Study	COMPLETED	Placebo to Match Vandetanib 100 mg and 300 mg	9
Overall Study	NOT COMPLETED	Vandetanib at the Dose of 100 mg	5
Overall Study	NOT COMPLETED	Vandetanib at the Dose of 300 mg	1
Overall Study	NOT COMPLETED	Placebo to Match Vandetanib 100 mg and 300 mg	2

Source ClinicalTrials.gov

Adverse events189

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	RIGHT HYPOCHONDRIUM PAIN	Gastrointestinal disorders	Vandetanib at the Dose of 100 mg	0	16	0
other	RIGHT HYPOCHONDRIUM PAIN	Gastrointestinal disorders	Vandetanib at the Dose of 300 mg	0	12	0
other	RIGHT HYPOCHONDRIUM PAIN	Gastrointestinal disorders	Placebo to Match Vandetanib 100 mg and 300 mg	1	11	1
other	AST ELEVATION	Blood and lymphatic system disorders	Vandetanib at the Dose of 100 mg	0	16	0
other	AST ELEVATION	Blood and lymphatic system disorders	Vandetanib at the Dose of 300 mg	0	12	0
other	AST ELEVATION	Blood and lymphatic system disorders	Placebo to Match Vandetanib 100 mg and 300 mg	1	11	1
other	RECTAL BLEEDING	General disorders	Vandetanib at the Dose of 100 mg	0	16	0
other	RECTAL BLEEDING	General disorders	Vandetanib at the Dose of 300 mg	0	12	0
other	RECTAL BLEEDING	General disorders	Placebo to Match Vandetanib 100 mg and 300 mg	1	11	1
other	HEMORRHOIDS	General disorders	Vandetanib at the Dose of 100 mg	0	16	0

1 to 10 of 189Source ClinicalTrials.gov

See all 189 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Vandetanib at the Dose of 100 mg
Total, all-cause mortality	Vandetanib at the Dose of 300 mg
Total, all-cause mortality	Placebo to Match Vandetanib 100 mg and 300 mg
Total, other adverse events	Vandetanib at the Dose of 100 mg	12	16
Total, other adverse events	Vandetanib at the Dose of 300 mg	11	12
Total, other adverse events	Placebo to Match Vandetanib 100 mg and 300 mg	6	11
Total, serious adverse events	Vandetanib at the Dose of 100 mg	3	16
Total, serious adverse events	Vandetanib at the Dose of 300 mg	2	12
Total, serious adverse events	Placebo to Match Vandetanib 100 mg and 300 mg	1	11

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
12684431	BACKGROUND

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00752986

GET https://conductscience.org/api/trials/v1/NCT00752986/events?page=2

API reference For AI assistants